Preclinical studies have shown that CAR-NK cells targeting CD70 exhibit enhanced cytotoxicity against osteosarcoma cell lines, but the clinical relevance of CD70 expression in osteosarcoma patients remains to be validated (72, 73). This evidence concerns the gene CD70 and osteosarcoma.